Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART).

Taigo KatoYuzo NakanoFumiya HongoHidenori KatanoTomoaki MiyagawaKousuke UedaHaruhito AzumaMasahiro NozawaNobuyuki HinataJunichi HoriTaiyo OtoshiNobuaki ShimizuMana AizawaShingo OsadaAkiko MatsuiMototsugu OyaMasatoshi EtoYoshihiko TomitaNobuo ShinoharaHirotsugu Uemura

Published in: International journal of urology : official journal of the Japanese Urological Association (2023)

We report the first real-world evidence of the effectiveness and tolerability of first-line avelumab plus axitinib in Japanese patients with aRCC. Results were comparable with the JAVELIN Renal 101 trial.

Keyphrases

renal cell carcinoma
metastatic renal cell carcinoma
cross sectional
open label
randomized controlled trial
study protocol
phase iii
double blind
clinical trial
systematic review
phase ii
stem cells
metabolic syndrome
skeletal muscle
weight loss